Stephens Consulting LLC Has $67,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Stephens Consulting LLC cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 19.8% during the 1st quarter, Holdings Channel reports. The firm owned 81 shares of the company’s stock after selling 20 shares during the quarter. Stephens Consulting LLC’s holdings in Eli Lilly and Company were worth $67,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of LLY. FWG Holdings LLC boosted its holdings in shares of Eli Lilly and Company by 0.6% during the 4th quarter. FWG Holdings LLC now owns 2,023 shares of the company’s stock worth $1,640,000 after buying an additional 12 shares during the period. Morling Financial Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 4.7% during the 4th quarter. Morling Financial Advisors LLC now owns 266 shares of the company’s stock worth $205,000 after buying an additional 12 shares during the period. Prestige Wealth Management Group LLC boosted its holdings in shares of Eli Lilly and Company by 2.0% during the 4th quarter. Prestige Wealth Management Group LLC now owns 606 shares of the company’s stock worth $468,000 after buying an additional 12 shares during the period. Applied Finance Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 1.4% during the 4th quarter. Applied Finance Capital Management LLC now owns 855 shares of the company’s stock worth $660,000 after buying an additional 12 shares during the period. Finally, Garner Asset Management Corp boosted its holdings in shares of Eli Lilly and Company by 2.3% during the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock worth $411,000 after buying an additional 12 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $807.62 on Tuesday. The company has a 50 day moving average of $777.10 and a 200-day moving average of $801.77. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company has a market cap of $765.41 billion, a PE ratio of 68.97, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Eli Lilly and Company’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.58 earnings per share. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 48.82%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Hsbc Global Res downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and cut their price objective for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Wall Street Zen raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, June 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.